Esperion Therapeutics
ESPR
ESPR
165 hedge funds and large institutions have $1.6B invested in Esperion Therapeutics in 2017 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 49 increasing their positions, 51 reducing their positions, and 28 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more capital invested
Capital invested by funds: $ → $
more funds holding
Funds holding: →
5% more call options, than puts
Call options by funds: $51.9M | Put options by funds: $49.2M
4% less repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 51
1.29% less ownership
Funds ownership: 94.04% → 92.75% (-1.3%)
Holders
165
Holding in Top 10
8
Calls
$51.9M
Puts
$49.2M
Top Buyers
| 1 | +$23.3M | |
| 2 | +$21.2M | |
| 3 | +$19.8M | |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$17.4M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$15.1M |
Top Sellers
| 1 | -$42M | |
| 2 | -$20.7M | |
| 3 | -$20.3M | |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$13M |
| 5 |
Credit Agricole
Montrouge Cedex,
France
|
-$7.91M |